Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug ...
Two impressive studies in lung cancer and another in breast cancer made Sunday a stellar day for AstraZeneca at the ASCO congress. Three of the group’s top cancer drugs were on display – EGFR ...
Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reported at the ASCO congress.
Posters and slides will be available to registered attendees at the scheduled session start time. Please refer to the Program Guide for more session details. A ...
The 2026 ASCO Breakthrough Meeting will offer novel research and expert, multidisciplinary perspectives on the newest scientific findings, clinical and technology advances, and treatment approaches ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results